The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.
Gilead removed two specific operational risks from its 2025 filing - one addressing manufacturing difficulties at third-party manufacturers and another covering safety issues for marketed products and candidates - suggesting either resolution of these concerns or integration into broader risk disclosures. The company substantively modified 10 risk factors, with notable revisions to forecasting challenges, corporate responsibility exposures, product-specific risks, and regulatory compliance matters, indicating evolving business priorities and risk management focus. No new risk categories were introduced in 2025, while 12 risk factors remained substantively unchanged.
Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.
🔴 No Match in Current Filing
We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.
🔒
🔴 No Match in Current Filing
We are subject to risks if significant safety issues arise for our marketed products or our product candidates.
🔒
🟡 Modified
We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories.
🔒
🟡 Modified
Our aspirations, goals and disclosures related to corporate responsibility matters expose us to numerous risks, including risks to our reputation and stock price.
🔒
🟡 Modified
Certain of our products subject us to additional or heightened risks.
🔒
🟡 Modified
We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the healthcare industry.
🔒
🟡 Modified
Climate change and natural disasters, as well as legal, regulatory, or market measures to address climate change, can negatively affect our business and operations.
🔒
🟡 Modified
We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption.
🔒
🟡 Modified
Our success depends on developing and commercializing new products or expanding the indications for existing products.
🔒
🟡 Modified
Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance, including if significant safety issues arise for our marketed products or our product candidates, could delay or halt commercialization of our products.
🔒
🟡 Modified
We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions.
🔒
🟡 Modified
We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, or we may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners, which could limit our ability to generate revenues.
🔒